There are many factors contributing to a successful IVF cycle. One of these is identifying the optimal time (or window of implantation) for embryo implantation. By analyzing the endometrium’s tissue through genetic testing, MIRA identifies each patient’s window of implantation, providing you and your patients with a personalized recommendation for future embryo transfers.
The optimal time for embryo transfer varies among individuals
Large scale studies have shown that 30% of infertility patients have a displaced window of implantation (WOI). This is why it is imperative to use MIRA to assess endometrial receptivity to determine the optimal time and day for embryo transfer.
Note：Courtesy of Katzorke, N et al. “Diagnosis of Endometrial-Factor Infertility: Current Approaches and New Avenues for Research.”
Geburtshilfe und Frauenheilkunde vol. 76,6 (2016): 699-703. doi:10.1055/s-0042-103752
Benefits of using MIRA
MIRA has a successful implantation rate of over 70%
Reduce IVF Treatment Cycles
Transferring the embryo at the right time can decrease the overall number of IVF treatment cycles needed before obtaining a successful pregnancy
Stable and Sensitive miRNA Biomarkers
MIRA can provide high quality results even with low sample amounts or low quality samples, vastly reducing the resampling and fail rate of test by more than 50% compared to other technologies
Faster Turnaround Time
With the ability to perform decentralized testing, MIRA’s service can be performed directly onsite, shortening the turnaround time for results to as quick as just one-third of the time of competing technologies
When to perform the MIRA biopsy during an IVF treatment cycle?
MIRA is compatible with both Natural Cycles and Hormone Replacement Therapy Cycles
NC: Day 7 after LH Surge or hCG Administration
HRT: Day 5 after Progesterone Administration
LH: Luteinizing Hormone Surge
hCG: Human Chorionic Gonadotropin Administration
MIRA Sample Submission Process
A simple procedure that can be done directly at your fertility clinic. A MIRA sample submission kit is included to provide the tools needed for collecting an endometrial biopsy sample for the analysis
Complete the Forms
Fill out the Sample Submission Form and ask the patient to complete the Consent Form (included in the kit).
Schedule the Biopsy
Endometrial biopsy should be scheduled either by natural cycles or hormone replacement therapy cycles*
Obtain the Sample
Place the endometrial biopsy in the MIRA cryotube. Make sure the sample is immersed in the preservation solution.
Store the Sample
Label the MIRA cryotube with sample details and store the tube at 4°C for at least 4 hours.
Ship the Sample
Ship the package at room temperature to the designated shipping address using priority or next day shipping.
Endometrial biopsy should be taken either:
After 5 days (120 hours) of progesterone administration in a hormone replacement therapy (HRT) cycle. Or, after 7 days (168 hours) from human chorionic gonadotropin (hCG) administration in a natural cycle.
What can MIRA tell you?
MIRA analyzes the endometrial biopsy and identifies the optimal implantation time so that you can perform a personalized embryo transfer during your patient’s next treatment cycle.
Receptive: Best Time to Implant
In the Window of Implantation (WOI)
A receptive result on the report indicates that the time of the tissue biopsy was the optimal time for embryo transfer and the same conditions and timing can be used during their subsequent treatment cycles for the most favorable personalized embryo transfer conditions.
Non-receptive: Adjust Implantation Time
NOT in the Window of Implantation (WOI)
A non-receptive result on the report indicates that the time of the tissue biopsy was not in the optimal time period for embryo transfer (pre- or post-receptive) and that the timing of embryo transfer for the patient should be altered in order to increase chance of successful implantation.
Inconclusive: The analysis was not able to determine the optimal time for embryo transfer. This could be the result of a low quality or low quantity biopsy sample. A MIRA representative will follow up with you to discuss altering the steps of the biopsy in order to retest your patient for a more comprehensive result. An inconclusive result happens in less than 1% of results.